
    
      Methods: The investigators will recruit 50 patients with severe psoriasis who received
      ustekinumab and 50 control subjects without psoriasis from August 2014 to July 2016.
      Concentrations of microparticles with expression for surface markers (Annexin V, CD31, and
      CD41a) will be measured in peripheral blood using flow cytometry.
    
  